

## Surveillance proposal consultation document

### 2022 surveillance of early and locally advanced breast cancer: diagnosis and management (NICE guideline NG101)

The consultation includes the following questions:

1. Do you agree with the proposal not to update [section 1.9 bisphosphonate therapy](#), the use of adjuvant bisphosphonates in people with early or locally advanced breast cancer in the guideline on [early and locally advanced breast cancer](#)?

Please could let us know if you agree or disagree (yes/no) and provide your comments regarding the reason for your response

2. Do you think that recommendations on adjuvant bisphosphonate therapy need information about assessment of vitamin D levels before starting bisphosphonates, and on the use of calcium and/or vitamin D supplements during treatment, in addition to what the BNF has already covered?

Please could let us know if you agree or disagree (yes/no) and provide your comments regarding this

3. Do you think that recommendations 1.9.1 and 1.9.2 need further clarification about approaches to adjuvant bisphosphonate therapy in patients who go through an early menopause due to chemotherapy?

Please could let us know if you agree or disagree (yes/no) and provide your comments regarding this

4. Do you have any comments on equality issues?

Please could let us know if you agree or disagree (yes/no) and provide with your comments regarding this

**Please note:** Responses to consultation questions will need to be submitted online, by signing into your NICE account. The consultation closes at 5pm on Thursday, 21<sup>st</sup> July 2022.